drugset
drugset / Trial / NCT03979014

Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia

NCT03979014 ↗

Phase 3 Completed 1099 enrolled Imperial College London Karolinska Institutet · collabMerck Sharp & Dohme LLC · collabNational Institute for Health Research, United Kingdom · collab
RandomizedParallel-groupSingle-blindPrevention

Summary

The researchers involved in this new study are interested in whether giving a HPV vaccine to women at the same time as conisation can lead to a greater rate of HPV clearance compared to conisation on its own, and a result reduce the occurrence of further infection and high grade CIN. The study will do this by using a specific HPV vaccine called Gardasil 9™ which protects against 9 types of HPV infection (types 6, 11, 16, 18, 31, 33, 45, 52 and 58).

Timeline

Start
2019-11-01
Primary completion
2025-09-05
Completion
2025-09-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gardasil 9 Vaccine 0.5 ml —

Indications

neoplasm